Postoperative Bleeding Halts Fibrin Pad Trial; Omrix Falls

Boggs, Jennifer
October 2008
BioWorld Today;10/10/2008, Vol. 19 Issue 198, p1
The article discusses the suspension by Omrix Biopharmaceuticals Inc. of the Phase II study of the Fibrin Pad product to investigate an incident of postoperative bleeding. The Fibrin Pad is made of a biodegradable matrix coated with human fibrinogen and thrombin and is designed to help form instant clots for rapid control of bleeding and for possible use on active bleeding sites. The interim analysis from the study is also discussed.


Related Articles

  • Postoperative Bleeding Halts Fibrin Pad Trial.  // Bioworld Week;10/13/2008, Vol. 16 Issue 41, p4 

    The article cites a report from Omrix Biopharmaceuticals Inc. which reveals that Phase II study of its Fibrin Pad product has been suspended to investigate an incident of postoperative bleeding. The study showed that the Fibrin Pad was superior to Surgicel in controlling mild to moderate soft...

  • FDA licenses human thrombin product. Traynor, Kate // American Journal of Health-System Pharmacy;10/1/2007, Vol. 64 Issue 19, p1994 

    The article reports on the approval of the Food and Drug Administration (FDA) of the licensing of Evithrom human thrombin as an aid to homeostasis during surgery. FDA said that Evithrom is the first human thrombin product to be approved in more than 50 years and the only product currently...

  • Topical human thrombin helps arrest bleeding. Belden, Heidi // Drug Topics;10/22/2007, Vol. 151 Issue 20, Special Section p4 

    The article offers information on the topical human thrombin which helps prevent bleeding. It is posed that Evithrom is from Omrix Biopharmaceuticals and Johnson & Johnson Wound Management. Relative to this, the Biological License Application was cleared by the United States Food and Drug...

  • fibrinogen. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p308 

    An encyclopedia entry for the term "fibrinogen" is presented. It refers to the protein which is found in the blood and is transformed into fibrin during the process of blood clotting.

  • Omrix resumes fibrin pad study.  // Medical Device Daily;11/4/2008, Vol. 12 Issue 215, p3 

    The article reports on the resumption of the Fibrin Pad U.S. Phase II clinical trial in mild-to-moderate bleeding by Omrix Biopharmaceuticals in November 2008. The features of the Fibrin Pad are described. On October 9, the company has announced the suspension of the U.S. Phase II clinical trial...

  • Recombinant Factor VIIA, its Clinical Properties, and the Tissue Factor Pathway of Coagulation. Bosinski, Timothy J.; El Solh, Ali A. // Mini Reviews in Medicinal Chemistry;Oct2006, Vol. 6 Issue 10, p1111 

    Recombinant factor VIIa (rFVIIa) is a synthetic coagulation protease that is structurally similar to humanderived plasma FVIIa. Pharmacologic doses of rFVIIa have been shown to enhance thrombin generation and assist in forming stable fibrin plugs at the site of injury. Recombinant factor VIIa...

  • Supplementation of fibrinogen in acquired bleeding disorders: experience, evidence, guidelines, and licences. Ranucci, M.; Solomon, C. // BJA: The British Journal of Anaesthesia;Aug2012, Vol. 109 Issue 2, p135 

    No abstract available.

  • Peri-partum reference ranges for ROTEM® thromboelastometry. de Lange, N. M.; van Rheenen-Flach, L. E.; Lancé, M. D.; Mooyman, L.; Woiski, M.; van Pampus, E. C.; Porath, M.; Bolte, A. C.; Smits, L.; Henskens, Y. M.; Scheepers, H. C. // BJA: The British Journal of Anaesthesia;May2014, Vol. 112 Issue 5, p852 

    Background Post-partum haemorrhage (PPH) causes rapidly developing deficiencies in clotting factors and contributes to substantial maternal morbidity and mortality. Rotational thromboelastometry (ROTEM®) is increasingly used as a point of care coagulation monitoring device in patients with...

  • Effect of Deglycosylation on the Fibrin Polymerization Depending on NaCl Concentration. Kenji Kubota; Yoshiharu Toyama; Nobukazu Nameki; Kaori Wakamatsu // Key Engineering Materials;2014, Vol. 596, p213 

    Cleavage of carbohydrate chains linked to fibrinogen molecule results in an acceleration of fibrin polymerization, fibrin gel formation, by promoting the lateral aggregation of protofibrils. Sialic acid at the unreduced terminus of carbohydrate chain plays an essentially important role in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics